Xing is a PhD student at the Monash Institute of Pharmaceutical Sciences. Her PhD project, Optimising Antimicrobial Dosing for Specific Patient Groups Through Pharmacokinetic and Pharmacodynamic Modelling to Combat Antimicrobial Resistance, focuses on developing PK/PD models and simulation-based strategies to improve antimicrobial therapy. She is passionate about using quantitative pharmacology to optimise dosing and support global efforts to combat antimicrobial resistance.

Viktorija Erdeljić Turk, MD, PhD, is a physician and consultant clinical pharmacologist at the University Hospital Centre Zagreb, Croatia. Her career has developed across hospital medicine, academia, and regulatory science. Her main professional interests include therapeutic optimization, drug safety, rational use of medicines, and antimicrobial stewardship. She teaches medical and pharmacy students in Croatian, English, and German at the Universities of Zagreb, Rijeka, and Osijek, and has mentored many trainees in clinical pharmacology. She is an experienced clinical trialist with extensive involvement in industry- and academia-sponsored studies. She also serves as an external expert to the Croatian Agency for Medicinal Products and Medical Devices and the European Medicines Agency. Her early work with UNHCR, UNICEF, and WHO contributed to her strong commitment to socially responsible and evidence-based medicine.

Dr Eshetie Melese Birru is a pharmacologist and pharmacist with expertise spanning pharmacy, pharmacology, clinical trials, and translational research. He is currently a Postdoctoral Research Officer at The Kids Research Institute Australia and an Adjunct Research Fellow at The University of Western Australia. He completed his PhD at Curtin University in 2025, focusing on clinical pharmacology studies of benzathine benzylpenicillin, and holds a Bachelor of Pharmacy and a Master of Science in Pharmacology. Dr Birru has extensive academic and research experience, previously serving as a pharmacology and pharmacy educator at the University of Gondar, Ethiopia, where he contributed to teaching, curriculum development, postgraduate supervision, and institutional ethics governance. His research interests include preclinical and clinical pharmacology, pharmacokinetics, public health, and implementation science, with a strong emphasis on improving the safety, delivery, and equitable access to essential medicines. He has contributed to preclinical and multicentre clinical trials, multidisciplinary collaborations, and peer-reviewed publications in international journals.

Sharon Sawe is a PhD student in Pharmacometrics at the University of Cape Town, in the Division of Clinical Pharmacology. She is originally from Kenya, with a background in biostatistics and data science. Her research focuses on the pharmacokinetics and pharmacodynamics of second-line tuberculosis drugs in pregnant and breastfeeding women, populations often excluded from clinical trials. She applies mathematical modelling to understand drug disposition during pregnancy and lactation, and to support evidence-based dosing in these groups. She is passionate about maternal and child health and using pharmacometrics to improve treatment outcomes in understudied populations.

Vaishanavi Bamane, Pharm.D., a Research Fellow (Medical) at ACTREC, TMC, Mumbai, specializes in oncology therapeutics and clinical pharmacology. Her research focuses on population pharmacokinetics, exposure–response analysis, and dose optimization of anti-infective and anticancer therapies in special populations plus actively involved in prospective and observational clinical studies and has a strong interest in translational pharmacology, precision dosing, and regulatory science.

Van Dong Nguyen, PharmD, MSc, is a clinical pharmacist with 10 years of experience at the McGill University Health Centre (MUHC), specializing in antimicrobial stewardship and clinical pharmacokinetics. He completed his PharmD and an MSc in Population Health at the Université de Montréal in 2014 and 2023 respectively, as well as a hospital pharmacy residency at the MUHC in 2015. He is currently a PhD candidate at the Université de Montréal Faculty of Pharmacy, where his research focuses on advancing vancomycin PopPK modeling in intermittent high-flux hemodialysis to improve individualized dosing strategies and identifying ideal candidates for MIPD for antimicrobial therapy in the critical care setting. He also teaches as a recurrent guest lecturer and course instructor.